Navigation Links
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
Date:11/20/2008

REINACH, Switzerland, November 20 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) announced today that the Anti-infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 17 to 2 against the approval of intravenous iclaprim, an antibiotic currently in development for the treatment of patients with complicated skin and skin structure infections (cSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Arpida remains confident in the efficacy and safety of intravenous iclaprim and its potential in combating serious resistant infections. Iclaprim has been tested against both vancomycin and linezolid, and in combined Phase III studies that included nearly 1,000 patients with cSSSI, iclaprim has been shown to have high cure rates, exceeding 90 percent in the Per-Protocol population. Iclaprim has demonstrated potent bactericidal (killing) activity against MRSA and an extended range of resistant pathogens, with a well tolerated side-effect profile. Arpida is fully committed to iclaprim's development and will continue to work with the FDA to address any questions related to iclaprim in anticipation of the drug's Prescription Drug User Fee Act (PDUFA) goal date of January 16, 2009.

In addition to the FDA regulatory application, the European Medicines Agency (EMEA) accepted intravenous iclaprim for review August 2008. In September 2008, Arpida filed a New Drug Submission for intravenous iclaprim in Canada.

Arpida continues to study the potential of iclaprim, including investigation of an oral formulation. In early 2008, Arpida received FDA approval to conduct a Phase II iclaprim 'intravenous-to-oral' switch trial in patients with cSSSI. Patient enrolment was completed in September 2008 and results are expected in December 2008.

Additional studies are ongoing worldwide to investigate the use of intravenous iclaprim in hospital-acqui
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arpida Invited to Present Data on Iclaprim at Scientific Conference
2. Arpida Provides Further Comments on the Pivotal Phase III Trials
3. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
4. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
7. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
8. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
9. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
10. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
11. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Pa., Sept. 9 DeVilbiss Healthcare has selected Business ... the successful implementation of its Microsoft Dynamics AX solution. ... Sunrise Medical, DeVilbiss sought to select and implement a ... successful medical device manufacturer. The primary ...
... Sept. 9 Diplomat Specialty Pharmacy announced today they have earned ... ranking of the fastest-growing private companies in America. "We,re ... earning a position of 554 in the nation, but if you ... are even more remarkable," stated Phil Hagerman, President and CEO of ...
Cached Medicine Technology:Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare 2Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
(Date:7/11/2014)... 2014 The American Association of Poison ... centers are commending Senator Bill Nelson (D-FL) for his ... 2014 on July 10, 2014. Along with fellow Senate ... Commission (CPSC) to enact rules requiring safer, child-resistant packaging ... , Senate co-sponsors of the bill include: Sen. Richard ...
(Date:7/11/2014)... 2014 As transvaginal mesh lawsuits ... & Johnson’s Ethicon Inc. unit continue to mount ... the Texas Attorney General’s Office has acknowledged that ... mesh products used to treat pelvic organ prolapse ... from kens5.com, the probe began nearly two years ...
(Date:7/11/2014)... News) -- People with the lowest incomes may have a ... (PAD), a new study suggests. People with PAD have ... most often the legs. The condition causes leg pain and ... the body. People with PAD have a higher risk for ... 6,800 people with PAD who took part in the U.S. ...
(Date:7/11/2014)... 2014 Microbiology testing is a highly ... industry, which is expected to pose the biggest challenge ... owes its growth to the ongoing spread of AIDS ... and a major factor leading to the upsurge of ... and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
Breaking Medicine News(10 mins):Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3
... testing breast tumors for HER2 ( http://www.mayoclinic.com/health/breast-cancer/AN00495 ) proteins ... of tumor (a single tumor block) is analyzed. However, ... ( http://www.mayoclinic.org/ ) found that HER2 results can vary ... tumor blocks are analyzed. This could have significant ...
... News) -- Americans who live in walkable neighborhoods are ... a higher quality of life, a new study suggests. ... stroll to such destinations as parks and playgrounds, club ... coffee shops and restaurants, explained study author Shannon Rogers ...
... from a specialized scan, radiation oncologists at Mayo Clinic ... number of lymph nodes critical for removing fluid from ... VIDEO ALERT: Additional audio and video resources, including excerpts ... researchers presenting at San Antonio Breast Cancer Symposium, are ...
... GeparQuinto study, randomized Phase III efficacy data on the ... early breast cancer will be presented at the 33rd ... von Minckwitz, M.D., Ph.D., managing director of the German ... efficacy data from this study, which will detail the ...
... Dec. 10 (HealthDay News) -- Children and teens accounted for ... treated in U.S. emergency departments between 1997 and 2006, a ... such heat-related injuries also increased 133 percent during the study ... according to the researchers at the Center for Injury Research ...
... of circulating tumor cells (CTCs) cells that have detached ... the blood are an independent prognostic marker in metastatic ... CTC level during therapy was found to be an early ... series validating the prognostic value of CTCs in first-line chemotherapy ...
Cached Medicine News:Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 2Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 3Health News:Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say 4Health News:'Walkable' Communities More Close-Knit, Study Finds 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 2Health News:Novel imaging technique may reduce lymphedema in breast cancer patients 3Health News:Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented 2Health News:Children, Teens Account for Half of Exercise-Related Heat Injuries 2Health News:High CTC levels predicted poor outcome in metastatic breast cancer 2
Sub Pectoral Bra...
Bandeau Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test ... Ischemia Modified Albumin (IMA®) by measuring the ... patient serum sample. First identified in the ... albumin comes in contact with ischemic tissue ...
Medicine Products: